We typically launch four companies a year built on Queen Mary research, 92% of which is world leading or internationally excellent (REF 2021). Queen Mary spinouts have raised over £120m of investment since 2020.
Our spinouts and social ventures are creating new uses for AI, life changing diagnostics and treatments, and sustainable solutions to the climate and nature crisis.
iHeF can screen for heart failure from a routine Electrocardiogram (ECG) recording by detecting changes in the heart’s structure and pumping functions.
A unique nutrient-based appetite suppressant which releases your body’s natural ability to control your eating – based on a decade of scientific research.
DAACI’s generative tech encodes composers’ musical ideas, allowing their AI to dynamically compose in real time without relying on pre-recorded samples.
At Queen Mary Innovation we work on behalf of Queen Mary University of London to maximise the impact of Queen Mary research using commercial tools, so we use the university’s Intellectual Property policy. The primary goal is to ensure economic and social impact, and any returns are shared with innovative creators and venture founders, reinvested in new ventures, or in the university’s charitable mission. You can find Queen Mary’s IP policy and commercialisation and benefit policy on our resources page.
